The Winter 2020 GOG Foundation, Inc. Educational Symposium is titled “It’s a PARP World After All” with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non‐members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, and other MDs engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse‐practitioners, and other interested Allied Health professionals. The speakers will focus their presentations on the use of PARP inhibitors across solid tumor disease types. PARP inhibitors have demonstrated efficacy in ovarian, breast, prostate, and pancreatic cancer.

The use of PARP inhibitor (PARPi) therapy has ushered in a new era and dramatically changed the management of ovarian cancer as well as several different solid tumor malignancies. “It’s a PARP World After ALL" GOG Foundation Symposium provides an excellent opportunity to explore the use of PARPi in ovarian, cervical, endometrial, breast, prostate, and pancreatic cancers. The latest practice-changing clinical trial results will be provided and reviewed in context with challenging clinical practice scenarios in cancer patients treated with PARPi. This symposium activity will provide evidence-based perspectives regarding controversial topics in ovarian and breast cancer management. The information that will be provided has potential practice-changing implications that be translated into the clinical arena immediately. Moreover, mechanisms of resistance to PARPi as well as the latest information on combination PARPi combinations will be reviewed. Interactive case vignettes will help attendees to better identify, manage, and mitigate PARPi toxicity. Ongoing and planned pivotal clinical trials will be discussed and the future of clinical trial design in the era of PARPi therapy will be explored.

LEARNING OBJECTIVES

Following this activity, participants will be better able to:

• Describe the development of PARP inhibitors and understand mechanism of action and development of resistance to PARP inhibition;
• Describe use of PARP inhibitors in gynecologic, breast, prostate, and pancreatic malignancies;
• Detail management of PARP inhibitor-related adverse events.